September is Pain Awareness Month, an opportunity to recognize not only how common chronic pain is, but how profoundly it can affect sleep, mobility, work, relationships, mental health and quality of life.

 

For people living with pain day after day, the question is rarely academic: Could cannabinoid therapy help me feel or function better?

 

For years, that question has often been simplified even further:

 

Does CBD help pain?

 

But as cannabinoid research develops, it is becoming increasingly clear that this may be too narrow a question.

 

CBD is a singular cannabinoid of the cannabis plant that contains hundreds of others, each with their own set of therapeutic values. This includes CBDA, CBG, CBC and THCA; all of which are increasingly being studied individually and in combination. Different types of chronic pain may also respond differently.

 

So, what does the current research actually tell us?

 

The Short Answer

 

Research suggests that some cannabinoid formulations may provide modest benefit for some people living with chronic pain, with the strongest randomized evidence currently concentrated in neuropathic pain and products containing THC.

 

At the same time, CBD alone has not consistently reduced chronic pain in controlled clinical trials. Research involving other cannabinoids and combinations is growing, but remains much less developed.

 

That does not mean cannabinoids either “work” or “do not work” for chronic pain. It means we need to ask better questions, such as:

 

What kind of pain? Which cannabinoids? In what combination? At what dose? By what route? For which patient and with what goal?

 

Those are much closer to the questions patients and healthcare professionals need answered.

 

First, Chronic Pain Is Not One Condition

 

“Chronic pain” describes pain that continues over time, but the mechanisms producing that pain can differ significantly.

 

Neuropathic pain originates from damage or dysfunction in the nervous system and may be experienced as burning, shooting, tingling or electric-like pain.

 

Nociceptive pain is associated with actual or threatened tissue injury and includes many forms of musculoskeletal and inflammatory pain, such as pain associated with osteoarthritis.

 

Nociplastic pain involves changes in how the nervous system processes pain even when clear ongoing tissue or nerve damage may not fully explain the symptoms. Fibromyalgia is one common example.

 

A person can also experience more than one pain mechanism at the same time. Therefore, a therapy that affects neuropathic pain may not produce the same result for arthritis, fibromyalgia, back pain or another chronic pain condition.

 

It is one reason broad statements such as “CBD works for pain” or “cannabis doesn’t work for pain” can be misleading.

 

Why Might Cannabinoids Affect Pain?

 

Cannabinoids interact directly and indirectly with the body’s endocannabinoid system (ECS), a signaling system involved in processes including pain perception, inflammation, mood, stress response and sleep.

 

The system includes cannabinoid receptors such as CB1 and CB2, naturally produced cannabinoids called endocannabinoids, and enzymes involved in producing and breaking those compounds down.

 

THC binds strongly to CB1 receptors, which are abundant throughout the central nervous system. Other cannabinoids, including CBD, interact with the ECS and other signaling pathways in more indirect ways.

 

Laboratory and preclinical research provides biological reasons to investigate cannabinoids for pain.But an important principle applies throughout cannabinoid research: Biological plausibility is not the same thing as demonstrated clinical benefit.

 

To understand whether cannabinoids actually improve chronic pain in people, we need human research.

 

What Does the Current Human Research Tell Us?

 

One of the most comprehensive recent assessments was a 2026 updated systematic review published in Annals of Internal Medicine. Researchers evaluated 25 randomized controlled trials involving more than 2,300 participants. Nearly two-thirds of participants had neuropathic pain.

 

The review found that products with relatively comparable amounts of THC and CBD, as well as products with a high THC-to-CBD ratio, were associated with small short-term improvements in pain compared with placebo.

 

The current evidence does not suggest that cannabis eliminates chronic pain. Instead, it suggests that particular formulations may produce a meaningful, but generally modest, improvement for some people. And the majority of controlled evidence still tells us much more about short-term treatment than it does about years of cannabinoid use.

 

What About CBD for Pain?

 

CBD has become nearly synonymous with hemp-derived wellness, and pain is one of the most common reasons people seek cannabinoid products.

 

But the clinical evidence requires some nuance.

 

The Agency for Healthcare Research and Quality’s ongoing systematic review of cannabis and chronic pain found that purified oral CBD alone was not associated with reduced pain intensity or improved function compared with placebo in the randomized trials evaluated.

 

That does not mean CBD has no biological activity related to pain or inflammation. Nor does it tell us that every CBD-containing formulation will produce the same result. What it does tell us is something important: CBD should not be treated as a stand-in for cannabinoid therapy as a whole.

 

For someone who has tried CBD without success, the conclusion may not necessarily be that the entire cannabinoid system is irrelevant to their pain. Likewise, evidence that a THC-containing formulation improves pain should not be used to claim that CBD alone will produce the same outcome.

 

Beyond CBD and THC: What About CBDA, CBG and Other Cannabinoids?

 

This may be one of the most interesting areas of emerging research.

 

Cannabis contains far more than CBD and THC, yet comparatively little human research has examined the therapeutic effects of other cannabinoids or combinations resembling the products people actually use.

 

A newly published 2026 study examined adults with fibromyalgia, rheumatoid arthritis and osteoarthritis who were assigned to one of three oral cannabinoid formulations:

 

• CBD and THC
• THCA, CBDA, CBG and CBC
• CBD and CBDA

 

Participants reported improvements across many measured symptoms over 12 weeks, and those receiving the THCA/CBDA/CBG/CBC formulation reported reductions in neuropathic pain intensity.

 

The findings are intriguing, particularly because the study begins to move beyond the traditional CBD-versus-THC conversation.

 

But they should also be interpreted carefully. Participants were comparing different active cannabinoid formulations rather than cannabinoid therapy against a placebo, and approximately 61% of those recruited completed all study questionnaires. The results can help generate better questions about cannabinoid combinations, but they do not establish that one particular combination is an effective treatment for chronic pain.

 

This is exactly where more research is needed.

 

Cannabis Is Not One Intervention

 

This is one of the central challenges in translating cannabinoid research into healthcare.

 

A clinical trial may investigate a precisely measured dose of purified CBD, synthetic THC or a standardized THC:CBD formulation.

 

A person seeking relief in the real world may encounter oils, tinctures, capsules, gummies, flower or topical products containing very different concentrations of:

 

• CBD
• THC
• CBDA
• THCA
• CBG
• CBC
• CBN
• terpenes
• and other plant compounds.

 

Routes of administration, doses, product quality, and individual metabolism all differ, affecting the outcome. Even products labeled with similar cannabinoid amounts may not necessarily represent the same therapeutic intervention.

 

Recent systematic reviews have specifically identified limited product detail and lack of evidence for whole-plant cannabis, topical CBD, minor cannabinoids and comparisons between cannabinoid products as major gaps in the research.

 

For patients, this can create an enormous gap between reading that “cannabis may help chronic pain” and knowing what that means for them.

 

That gap is where responsible education and healthcare conversations become essential.

 

Pain Relief Is About More Than a Number

 

Researchers often measure pain on a numerical scale: How would you rate your pain from 0 to 10?

 

But for someone living with chronic pain, success may also mean:

 

• sleeping through the night;
• walking farther;
• returning to work;
• cooking a meal;
• spending time with family;
• feeling less consumed by pain;
• reducing the burden of another medication; or
• simply having more good hours in a day.

 

This is one reason patient-reported outcomes and real-world evidence are important complements to clinical trials.

 

A small 2026 prospective observational study of patients receiving treatment through a university chronic pain clinic, for example, found reductions in reported pain and prescription opioid use after participants began medical cannabis. Because there was no randomized control group, the study cannot prove that cannabis caused those improvements, but it can help researchers identify outcomes worth studying in larger controlled trials.

 

Other observational research has similarly associated medical cannabis use with measures beyond pain intensity, including quality of life and healthcare utilization. These studies do not replace randomized clinical trials, but they do answer different questions. And when real-world observations repeatedly identify patterns, they can help determine what future clinical research should investigate.

 

Every Story Matters—Especially When We Collect It Responsibly

 

At Realm of Caring, we have spent more than a decade hearing from people seeking relief from chronic and debilitating conditions.

 

Some arrive after conventional therapies have not provided enough relief. Some hope to reduce unwanted side effects from existing medications. Some want an option that does not leave them feeling impaired. Others have already discovered a cannabinoid regimen that works for them and simply want to better understand what they are taking.

 

Those experiences cannot tell us that a therapy will work for everyone, but it does identify an important question and thousands of experiences collected systematically can begin to reveal patterns. And those patterns can inform the clinical studies, healthcare policies and medical conversations that follow.

 

That is why Realm of Caring supports both individual education and rigorous research participation. The goal is not to choose between lived experience and science. It is to build better science that reflects the questions patients are actually asking.

 

What We Still Don’t Know

 

Despite decades of cannabis use for pain and rapidly expanding research, important questions remain.

 

We still need to better understand:

 

• Which chronic pain conditions are most likely to respond to cannabinoid therapy?
• Which patients are most likely to benefit?
• What cannabinoid combinations are most effective?
• What role might CBDA, CBG, CBC, THCA and other cannabinoids, terpenes, and/or flavonoids play?
• What doses and routes of administration provide the best balance of benefit and risk?
• What are the effects of long-term cannabinoid use?
• How do cannabinoids interact with prescription medications?
• Can cannabinoid therapy safely reduce reliance on other pain medications for some patients?
• How do age, sex, genetics, metabolism and other health conditions influence response?
• How closely do commercially available products resemble the formulations evaluated in clinical research?

 

These gaps are all reasons to better investigate cannabinoids.

 

Considering Cannabinoid Therapy for Chronic Pain?

 

Cannabinoid therapy is not one-size-fits-all, and managing chronic pain rarely is either.

 

If you are considering cannabis or cannabinoids for pain, talk with a knowledgeable healthcare professional, particularly if you take prescription medications or live with other health conditions.

 

Consider not only whether you feel different, but what you are hoping to improve. Pain intensity? Sleep? Mobility? Ability to work? Quality of life?

 

Understand what cannabinoids are actually in the product you are using and look for products supported by independent testing.

 

And remember that more is not always better. THC in particular can cause intoxication, dizziness, sedation and other unwanted effects, and individual responses to cannabinoids vary significantly.

 

You Don’t Have to Figure It Out Alone

 

Realm of Caring provides free, one-on-one cannabinoid education to individuals and families navigating these questions every day.

 

Looking for support? Connect with our Care Team for individualized education and resources.

 

Already using or about to be using cannabinoids? Your experience can contribute to the evidence base. Learn about opportunities to participate in Realm of Caring-supported research.

 

Has access to your cannabinoid therapy affected your health or quality of life? Share your experience through Every Story Matters. The decisions being made about cannabinoid access should include the people whose health may be affected by them.

 

For more than a decade, patients have been asking whether cannabinoids can play a responsible role in managing chronic pain.

 

Research is beginning to provide better answers.

 

Now we have to keep asking better questions.

 

This information is provided for educational purposes and is not intended to diagnose, treat, cure or prevent any disease or replace individualized medical advice. Talk with your healthcare professional before beginning, stopping or changing any therapy.